B. Riley Securities maintains Agenus at Buy, raises price target to $16 from $14
B. Riley Securities kept its Buy rating on Agenus and increased its price target to $16 from $14, suggesting a 123.8% upside from the Nov 6 close of $7.15.
How this was made

The 30-second read
Why it matters
The higher target may attract new buying interest and support the stock price.
Market read
A modest analyst upgrade that could provide short‑term upside for traders.
What to watch
Potential regulatory or trial setbacks not reflected in the rating.
Background
Analyst rating maintenance with an upgraded price target.
Ticker impact
B. Riley raised Agenus price target to $16 from $14, indicating a bullish outlook.
potential upward pressure as investors price in the higher target
Target increase reflects improved expectations; no immediate catalyst beyond the rating change.
Market effects
May lift sentiment in the biotech sector as analysts show confidence in Agenus.
Limited to U.S. biotech investors.
Minimal global impact beyond niche biotech investors.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- CompanyAgenus Inc.
Biotech firm focused on immuno-oncology.
- Research FirmB. Riley Securities
Equity research analyst raising Agenus target.
